Biogen
Company specialized in the discovery, development, and delivery of therapies for the treatment of neurological diseases
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.
Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.
Visit website: https://www.biogen.com/
Details last updated 28-Sep-2019
People at Biogen
Biogen News
The future of longevity: investing in the next biotech revolution
The Motley Fool - 13-Aug-2024
How lifespan-extending drugs could shape the next biotech boom
Read more...Biogen discontinues controversial Alzheimer's drug Aduhelm
Independent - 31-Jan-2024
Once hailed as a breakthrough, Aduhelm faces final curtain after limited use and insurance hurdles
Read more...Eisai's Lecanemab drug proves to slowdown Alzheimer's disease, unlike aducanumab drug
BBC - 28-Sep-2022
Historic moment for dementia research-large clinical trial to successfully slow cognitive decline
Read more...For the first time in 20 years, FDA approved new drug to treat Alzheimer's disease
BBC - 08-Jun-2021
A long way from a cure, but hopefully indicates that Alzheimer's isn't unassailable
Read more...First therapy that could slow Alzheimer's disease
BBC - 22-Oct-2019
Groundbreaking drug is called aducanumab, which targets a protein called amyloid
Read more...Biogen's Alzheimer's drug trials halted
CNN - 21-Mar-2019
Another promising candidate not making it to the finish line
Read more...Alzheimer’s progress slowed by plaque-busting drug
New Scientist - 25-Mar-2015
In a small trial, the drug slowed the progression of the disease and reduced deposits of amyloid ...
Read more...